10-K: Ayala Pharmaceuticals Faces Going Concern Uncertainty After Asset Sale, Reports $48.1 Million Net Loss in 2023

Ayala Pharmaceuticals reports a significant net loss of $48.1 million for 2023 and expresses substantial doubt about its ability to continue as a going concern after selling key assets to Immunome.

Summary

• Ayala Pharmaceuticals reported a net loss of $48.1 million for the year ended December 31, 2023, compared to a $38.0 million loss in 2022.
• The company used approximately $29.5 million in cash for operations during 2023.
• As of December 31, 2023, Ayala had $4.9 million in cash and cash equivalents, $25.0 million in current liabilities, and an accumulated deficit of $197.2 million.
• Following the sale of its AL101 and AL102 assets to Immunome for $20 million in cash and 2,175,489 shares of Immunome stock, Ayala received $13 million in cash, with Immunome paying $3 million of Ayala's liabilities directly to vendors.
• The company issued additional convertible notes and warrants for $2.0 million in funding on March 1, 2024.
• The proceeds from the asset sale and convertible notes are insufficient to cover existing liabilities, raising substantial doubt about Ayala's ability to continue as a going concern beyond May 2024.
• Ayala has reduced its workforce by approximately 50% in 2023 and terminated 18 additional employees and two officers in the first quarter of 2024, leaving the CEO as the only employee after June 25, 2024.
• The company's primary clinical asset is now aspacytarabine (BST-236) for the treatment of acute myeloid leukemia (AML).

Sentiment

Score: 2

Explanation: The document paints a concerning picture of the company's financial health and future prospects. The substantial net loss, going concern uncertainty, and significant workforce reduction indicate a high level of risk and a negative outlook from an investment perspective.

Positives

• The sale of AL101 and AL102 assets to Immunome provided an immediate cash infusion of $13 million and reduced liabilities by $3 million.
• The company secured an additional $2 million in funding through convertible notes and warrants.
• Ayala retains a pipeline asset in BST-236, a novel anti-metabolite for AML treatment.
• The company has a robust patent portfolio protecting its product candidates and Lm-based immunotherapy technology.

Negatives

• The company's cash reserves are insufficient to cover existing liabilities, raising substantial doubt about its ability to continue as a going concern.
• The company has incurred significant net operating losses since inception and expects to continue to incur significant expenses and increasing operating losses for the foreseeable future.
• The company has undergone a significant reduction in workforce, including the termination of key officers.
• The company is dependent on additional financing, including the sale of Immunome shares, to continue operations beyond May 2024.

Risks

• The company's ability to continue as a going concern is highly uncertain due to insufficient cash resources and the need for additional financing.
• Failure to secure additional funding or sell Immunome shares could force the company to delay, reduce, or eliminate research and development programs or cease operations.
• The company faces significant competition in the biotechnology and biopharmaceutical industries.
• The company's success depends on obtaining and maintaining proprietary protection for its product candidates.
• The company is subject to extensive government regulations, including the FDA approval process.
• The company's future success depends on the ability to obtain reimbursement for its products from government and private payors.

Future Outlook

The company anticipates that its expenses will decrease as it continues to conduct operations related to advancing the development of BST-236 and satisfies certain debts and obligations remaining from its operations prior to the consummation of the Asset Sale. The company requires additional financing to continue operations beyond May 2024.

Management Comments

• The company expects to be able to meet its financial obligations to its employees.
• The company can give no assurances that it will be successful in raising funds through the sale of a portion of the Immunome Shares or any other alternative.
• Any inability to so obtain additional financing or funding will likely cause the Company to cease business operations.

Industry Context

The biotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition. Ayala faces competition from established and emerging pharmaceutical and biotechnology companies, as well as universities and research institutions. The company's success depends on its ability to develop and commercialize its product candidates effectively and obtain regulatory approvals.

Comparison to Industry Standards

• The company's financial situation is concerning, as many biotech companies at this stage are still burning cash, but the level of cash burn and the lack of a clear path to profitability is a significant concern.
• The company's reliance on external funding and the uncertainty surrounding its ability to secure additional capital are not uncommon in the biotech industry, but the severity of the situation is notable.
• The company's workforce reduction is a common cost-cutting measure in the biotech industry, but the extent of the reduction and the departure of key officers is a significant concern.
• The company's focus on BST-236 for AML treatment is aligned with the industry's focus on targeted therapies for specific patient populations, but the company's ability to successfully develop and commercialize this product remains uncertain.

Management Changes

Legal Proceedings

• The company is involved in legal proceedings in the ordinary course of business, but does not believe any of these claims or proceedings are likely to have a material adverse effect on its financial condition or results of operations.
• A final settlement agreement relating to purported stockholder claims was entered into on March 21, 2024, and in connection therewith, the Company has accrued $ 200 thousand of expense.
• A stockholder of Ayala Pharmaceuticals, Inc. submitted a letter threatening legal action against the Company and alleging breaches of fiduciary duty in connection with several transactions.

Related Party Transactions

• Israel Biotech Fund I, L.P., Israel Biotech Fund II, L.P., and Arkin Bio Ventures L.P. hold 20% of the company each and have three affiliated directors on the board.
• The company entered into Convertible Note agreements with related parties in August and November 2023.
• The company entered into a Side Letter Agreement with related parties in November 2023.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees have been significantly impacted by workforce reductions and the termination of key officers.
• Customers and suppliers may be affected by the company's uncertain future and potential cessation of operations.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company needs to secure additional financing, potentially through the sale of Immunome shares or other means, to continue operations beyond May 2024.
• The company will continue to conduct operations related to advancing the development of BST-236.
• The company will satisfy certain debts and obligations remaining from its operations prior to the consummation of the Asset Sale.

Key Dates

Keywords

Ayala Pharmaceuticals, Immunome, Asset Sale, BST-236, Acute Myeloid Leukemia, AML, Going Concern, Convertible Notes, Warrants, Net Loss, Financial Risk, Biotechnology, Oncology, Clinical Stage, Listeria monocytogenes, Immunotherapy